Lars Johansson, CSO at Antaros Medical, will be presenting this week at the 3rd GLP-1-Based Therapeutics Summit. His talk ‘Underneath the lost kilos: Imaging insights for body composition, muscle changes and other downstream effects in GLP-1 RA trials’ will cover what we can look at with imaging-based body composition assessments, the differences we need to keep in mind when interpreting treatment effects, and some of the other key end-organ effects in the muscle, kidney, liver, heart, and brain that can be studied with imaging.
Incretin-based therapies, such as glucagon-like-peptide-1 receptor agonists (GLP-1 RAs) have changed the treatment landscape in type 2 diabetes (T2D), obesity, and other metabolic diseases. With further opportunities for combinations of incretins (dual and triple agonists), as well as other modes of action, and expansion into new disease indications, the growing trend regarding the number of incretin-based therapies in developnent is likely to continue.
To hear more about the value of imaging in GLP-1 trials, join us at the GLP-1-Based Therapeutics Summit on Wednesday 15 April @ 11:30 EDT to hear Lars’ talk. The GLP-1-Based Therapeutics Summit takes place from 14-16 April in Boston, MA.